ArticleFrontiers in immunology2025
Anifrolumab has a direct immunoregulatory effect on inflamed keratinocytes: implications for the treatment of lupus erythematosus skin lesions.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous lupus erythematosus (CLE) is an autoimmune skin disease characterized by a type I interferon (IFN)-driven interface dermatitis in which cytotoxic lymphocytes invade the basal layer of the epidermis and induce the keratinocytic cell death. Anifrolumab is a monoclonal antibody targeting the type I interferon receptor (IFNAR1) approved for the therapy of systemic lupus erythematosus (SLE). Recent clinical observations indicated that anifrolumab might be particularly effective in the treatment of lupus erythematosus (LE) skin manifestations. We hypothesize that anifrolumab does not only inhibit interferons circulating in the blood but also has a direct impact on keratinocytes. Our results show that IFNAR1 is expressed in lesional keratinocytes in CLE patients in immunohistochemistry. Gene expression analyses confirmed a strong activation of the interferon signaling pathway in CLE lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.